Ask AI

Think You Know JAK? Essential Evidence to Aid Your Clinical Implementation of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo

Understand the role of JAK-STAT signaling in the pathophysiology of atopic dermatitis, alopecia areata, and vitiligo. Then learn strategies for developing personalized treatment and monitoring plans with JAK inhibitors that balance the benefits vs risks, through expert-written ClinicalThought commentaries, downloadable slides, and an on-demand webcast.

Share

Program Content

Events

Activities

JAK inhibitors in alopecia areata
Improving Patient Satisfaction in Alopecia Areata: Rationale and Safety Considerations for JAK Inhibitors
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 02, 2026

Expires: July 01, 2027

JAK inhibitors in atopic dermatitis
Improving Patient Outcomes in Atopic Dermatitis: Rationale and Safety Considerations for JAK Inhibitors
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 07, 2026

Expires: July 06, 2027

JAK inhibitors for vitiligo
Optimizing Vitiligo Treatment With JAK Inhibitors: Patient Eligibility, Therapeutic Strategies, and Setting Expectations
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 09, 2026

Expires: July 08, 2027

Provided by

ProCE Banner

Provided by Partners for Advancing Clinical Education (Partners) in partnership with Decera Clinical Education and Smart Patients.

Supporters

Supported by an independent educational grant from AbbVie.

AbbVie

Partners

Decera Clinical Education

ProCE Banner

Smart Patients

ProCE Banner